Archive for October, 2019

October 8, 2019

On Monday morning in Bethesda, Maryland hundreds of industry leaders emerged from a large ballroom at the inaugural Bio Innovation Conference, hosted by Maryland Life Sciences, a division of the Maryland Tech Council.

After hearing the opening remarks attendees could only have felt one of two ways proud to be part of Marylands life sciences community or eager to become part of it.

Whether glad or envious, every attendee was primed for the day-long event filled with keynotes, panels and sessions made up of a whos who within Marylands cell and gene therapy and biomanufacturing industries.

Maryland Tech Council CEO Martin Rosendale, and many of his 190 life science member companies, see Maryland as the number one location to grow a biotech business, especially in cell and gene therapy. This event helped to solidify a powerful community around sharing that vision.

After introducing the events sponsors and partners Rosendale gave special recognition to the dozens of students in attendance. He made sure that all of the companies in attendance understood that the students who took the time to be part of the days event are the ones who will become the workforce that many of them will hire in the near future.

Workforce development is just one of the ways Maryland Life Sciences supports their member organizations who all desperately need highly qualified talent to be successful. Next to growth capital, access to talent is the top issue that almost all companies are facing.

The conference was also about coming together as one community to celebrate the regions success in cell and gene therapy, support one another, and grow the region.

Rosendale recounted one of his recent CapitalM podcasts where he asked Maryland Secretary of Commerce Kelly Shulz: How can we promote the BioHealth Capital Region? What can we do as business owners, entrepreneurs, and innovators?

She answered with one word. Stories. Tell stories.

From the stage, Secretary Shulz reiterated that.

Share stories and talk about all the great things that are happening in Maryland, particularly in biotech and life sciences.

Maryland ranks high among the states in life sciences. Fourth, in fact, according to GENs list of Top 10 BioPharma Clusters. Were very close to number three, she said. And were heading to number one.

Secretary Shulz emphasized the value of life science businesses to the state of Maryland. She wanted the students in the room to understand there was real opportunity in Marylands growing life sciences industry. According to the Secretary, the industry pays about $4.9 billion in wages within the state. Not a bad little career considering the average salary in life sciences is around $110,000. These are good jobs. Theyre meaningful jobs, she shared.

Secretary Schulz introduced one of Marylands prominent CEOs to share the days first story. A veteran of Silicon Valley, he came out of retirement to fund and found what is on its way to becoming yet another successful Maryland company: CEO of American Gene Technologies (AGT), Jeff Galvin.

Galvin opened with a major announcement.

AGT has completed its first Investigational New Drug (IND) application for its HIV gene therapy and is on-track to submit it to the U.S. Food and Drug Administration (FDA). If cleared AGT will be ready to advance its patented lead candidate for an HIV cure into the clinic.

In gene and cell therapy, the human trials are much more predictable than the old styles of drug development. So Ill tell you, Im 90% confident that in the next year, a company, in Maryland, will cure HIV. And thats a bold statement, Galvin announced.

Jeff Galvin shared with attendees that the T cells they put back into the body have the potential to protect an HIV infected individual from HIV. They become permanently immune to their own disease. They can never progress to AIDS. They dont have to take any additional meds. They can never be contagious, and they can never re-contract HIV.

Why is this all happening in Maryland? Galvin cites three important factors.

Galvin regards the BioHealth Capital Region, this amazing area chock full of technology, at the epicenter of gene and cell therapy. The Human Genome Project took place here, NIH is here, along with the University of Maryland, Johns Hopkins, and many great government research institutes and programs. With utter confidence, Galvin believes, we can make Maryland number one together.

Galvins enthusiasm seemed to fuel attendees with a level of excitement and energy that lasted throughout the whole day.

As Secretary Shulz recommended, the day was filled with stories. Everywhere you turned both panelists and attendees alike were sharing stories about their journeys in cell and gene therapy, what they were working on, and what excites them about the future of life science in Maryland. Some of the most valuable stories though were about the challenges and failures on the way to success.

One way attendees had the opportunity to share their stories was through the BIO One-on-One Partnering program. Touted as the most efficient way to do business in the life sciences industry, the system helped attendees to identify new potential partners, and request meetings with prospective investors and senior business development executives.

The result was hundreds of one-on-on partnering meetings that happened throughout the day making this event not only inspirational and educational but a place where deals were getting done to move businesses forward.

Another highlight was Keynote speaker, NIH NHLBIs John Tisdale, MD, a pioneer in the field who has spent twenty years dedicated to researching, treating and potentially curing Sickle Cell Anemia, a disease leading to the deaths of millions around the world. Tisdale spoke about why more efforts need to be invested in curing Sickle Cell and how advances in cell and gene therapies are now making the possibility of a cure become all that more probable.

What made this Keynote even more remarkable is that Tisdales wish came closer to a reality that very day. Local-company, MaxCyte, run by conference participant and CEO Doug Doerfler, had just announced a new collaboration with Editas Medicine, Inc. to help advancean experimental CRISPR medicine designed to durably treat sickle cell disease and beta-thalassemia. It was quite fitting that Doerfler was the one who introduced Tisdales keynote.

Other highlights included JLABS @ Washington DCs MichelleMcMurry-Heath, MD, PhD, as another keynote speaker, a workshop on attracting and retaining talent that engaged an audience of more than 60 people, and several sessions on cell and gene therapy, biomanufacturing, and investment and commercialization strategies.

During the day, attendees took their pride in being part of the Maryland life sciences community, or their desire to become part of it, into what became a highly successful first Bio Innovation Conference.

As Rosendale concluded in MTCs post-conference press release, The energy was high, and the feedback from attendees was positive. I believe the conference further demonstrates that this region has EXACTLY what it takes to be the number one life sciences hub.

Sherilyn is a freelance writer focused on connecting life science companies, patients, partners, and prospects. For over 20 years she has inspired engagement and action through writing in pharma sales management, patient engagement, storytelling, and content creation.

Read the original here:
The Story of Maryland's Cell and Gene Therapy Cluster Was Shared Loud and Clear at Inaugural Bio Innovation Conference - BioBuzz

New York, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Ewings Sarcoma Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023" - https://www.reportlinker.com/p05821758/?utm_source=GNW In 2018, the combination therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high efficacy of combination therapy in treating Ewings sarcoma will play a significant role in the combination therapy segment to maintain its market position. Also, our global Ewings sarcoma treatment market report looks at factors such as the growing awareness about and funding for Ewings sarcoma, regulatory incentives, and financial assistance programs and reimbursement schemes. However, lack of approved therapies for Ewings sarcoma, absence of predictive biomarkers in Ewings sarcoma, and side-effects of chemotherapy may hamper the growth of the Ewings sarcoma treatment industry over the forecast period.

Global Ewings Sarcoma Treatment Market: Overview

Financial assistance programs and reimbursement schemes

The increasing cost of therapeutics for the treatment of various indications is encouraging governments of various countries and pharmaceutical vendors to introduce several financial assistance programs and reimbursement schemes. There are several drug assistance programs that offer payment limitation programs for costly medications such as chemotherapeutics. GlaxoSmithKline, Merck, and Pfizer are some of the prominent vendors providing prescription drug assistance programs to patients. Such assistance programs increase the patient adherence to drug treatment which will eventually lead to the expansion of the global Ewings sarcoma treatment market at a CAGR of almost 6% during the forecast period.

Emergence of regenerative therapies

Regenerative medicines, including gene therapy, are gaining traction in the market. This is encouraging several pharmaceutical companies to study and develop a gene therapy to treat metastatic Ewings sarcoma and recurrent Ewings tumors. The new therapeutic methods help in minimizing tumor cell proliferation in advance Ewings sarcoma. For instance, Gradalis is conducting a Phase I clinical trial to evaluate pbi-shRNA EWS/FLI1 Type 1 LPX, an anti-stathmin gene therapy.The growing focus on advancing regenerative medicines in clinical phases is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global Ewings sarcoma treatment market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Ewings sarcoma treatment manufacturers, that include Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol-Myers Squibb Co., Eli Lilly and Co., Merck & Co. Inc., Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Also, Ewings sarcoma treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all future growth opportunities.Read the full report: https://www.reportlinker.com/p05821758/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Go here to see the original:
The global Ewing's sarcoma treatment market at a CAGR of almost 6% during the forecast period - GlobeNewswire

Oct. 10, 2019 09:16 UTC

AJDOVINA, Slovenia--(BUSINESS WIRE)-- BIA Separations, a leading bio-chromatography development and manufacturing company, today announced the introduction of its CORNERSTONE Exosome Process Development Solution, designed to help drug-developers overcome critical development bottlenecks in the preparation of exosomes for clinical use.

Introducing two proprietary new technologies central to highly pure and scalable purification, BIA Separations Exosome Process Development Solution represents the latest extension of its CORNERSTONE programs for the manufacture of gene therapy vectors, following the launch of its AAV program earlier this month.

Exosomes fulfil a critical role as communicators among cells, with targeting and message content depending on their surface receptors and payload. Their unique ability to deliver that payload to the right target makes them obvious candidates for an extensive range of therapeutic applications in the fields of cancer and regenerative medicine, including for neurodegenerative and cardio-pulmonary disorders.

For such clinical applications to be realised, thoroughly purified exosomes are required, with key contaminant classes such as host-cell proteins, host-cell DNA, and non-exosomal vesicles reduced to trace levels. BIA Separations new technology brings important new tools for this purification, whilst ensuring fast and efficient process development. The technology is easily scalable from lab to manufacturing, and is able to provide better product quality than traditional purification systems.

CORNERSTONE Exosome Development Solution is built on the capabilities of two novel technologies. Kryptonase is an integrated enzymatic treatment that reduces host-cell DNA and facilitates the removal of host-cell protein contaminants. The CIMmultus EV monolithic column is a chromatography device that eliminates non-exosomal vesicles, and concentrates exosomes in a low shear environment. The technologies are available as part of a comprehensive Process Development Service, in which BIA Separations experts design and optimize processes to support clinical trials and scale-up to industrial manufacturing. Translational scientists and process developers can also access both new products as a Process Development Pack for exosome research purposes.

Ale trancar, Chief Executive Officer at BIA Separations, said: Exosomes represent the next generation delivery strategy for nucleic acids and other therapeutics, as well as being evaluated as a platform for regenerative medicine with high hopes of bringing more therapeutic options to chronically ill patients. We are all looking forward to seeing the impact of our tools on this novel therapy space.

Pete Gagnon, Chief Scientific Officer at BIA Separations, added: Every new product class presents a unique new set of challenges and exosomes are no exception. Our new CORNERSTONE program embodies the decades of experience weve developed with the purification of viruses, DNA plasmids, mRNA, and other gene therapy products, and extends it to include exosomes. This gives our customers a head-start that will help them be first to the clinic and first to market.

To learn more about BIA Separations services and technology for therapeutic vectors, visit http://www.biaseparations.com/en/featured/cornerstone-process-solutions and http://www.biaseparations.com/en/featured/evs

Notes to Editors

For high resolution images, please email sarah.jeffery@zymecommunications.com

About BIA Separations: http://www.biaseparations.com

BIA Separations is the leading developer and manufacturer of CIM (Convective Interaction Media) monolithic chromatographic columns, and development of integrated processes for the production, purification, and analysis of large biomolecules such as gene therapy vectors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005344/en/

Read the original:
BIA Separations introduces CORNERSTONE Exosome Process Development Solution to Enable Industrial Scale Manufacture of Therapeutic Exosomes - BioSpace

The Progress 1000 is compiled every year. The theme of this years list is the future and technology, and embraces whole new sectors including augmented and virtual reality and cyber security, as well as a wide range of activists challenging inequality and helping the environment.

Dr Prasanna Sooriakumaran, a consultant prostate cancer surgeon at UCLH, was included for his pioneering robotic surgery. He is investigating new techniques to spare men with prostate cancer the potentially debilitating effects of surgery. Early trials show that his new technique has drastically reduced recovery time for up to 94 per cent of patients.

Prasanna said: It is a great honour to top the list of Londons most influential doctors in the Progress 1000 after having also made the list last year. This is a testament to the wonderful staff at UCLH, who provide world class care to men with prostate cancer.

Professor Bryan Williams is director of one of the UKs leading NIHR Biomedical Research Centres at UCLH, director of research at UCLH and Chair of Medicine at UCL. He is a clinician at UCLH and is recognised as one of the worlds leading authorities on high blood pressure.

He said: It is good to see recognition of the influence that staff at UCLH have in driving forward medical research and innovation in London and beyond.

Professor Charles Swanton, UCLs professor of personalised cancer medicine with a lab at UCL Cancer Institute and the Francis Crick Institute in Kings Cross, a consultant at UCLH and chief clinician at Cancer Research UK, is leading pioneering research on lung cancer. Professor Swanton studies how cancers evolve in the body to spread and become resistant to therapy. He is also researching ways to treat tumours more effectively.

Charlie said: This is a great testament to the hospital, university, Crick and CRUK and the team for making TRACERx possible.

Professor Tariq Enver, director at UCL Cancer Institute and professor of stem cell biology at UCL, leads a grand coalition in the war on cancer by encouraging closer working relations between UCL, Kings College London, Queen Mary University of London and the Francis Crick Institute, creating a centre of excellence for biotherapeutics.

Tariq said: It is fantastic that the vital work being done by the team in London - which has the potential to transform cancer treatment in the long run is being recognised and encouraged. Being nominated is a massive boost for all of us who have worked so hard to reach this point.

Professor Ravi Gupta, until recently an infectious diseases clinician at UCLHs Hospital for Tropical Diseases, studies the evolution and spread of HIV drug resistance globally. He, along with colleagues at Imperial College London, recently published a report on how a patient with HIV and lymphoma is now free from both conditions after an allogeneic stem cell transplant using cells from a donor lacking a critical receptor protein for HIV infection, CCR5. This work has rejuvenated the field of HIV gene therapy.

He said: It has been humbling to work at UCLH alongside such dedicated staff, both clinical and academic. I hope that recognition of the London Patient HIV cure in the Progress 1000 list will serve as an inspiration in London and beyond in the fight against HIV/AIDS.

Professor Chris Whitty, the chief medical officer for England and a UCLH physician, was included on the list for his work which focuses on the diagnosis and management of infectious diseases in children and adults.

More:
Six people with links to UCLH listed among most influential people in London - University College London Hospitals

LONDON Chances are, youve heard little or nothing about Rick Klausners startup Lyell. But that ends now.

Klausner, the former head of the National Cancer Institute, former executive director for global health at the Gates Foundation, co-founder at Juno and one of the leaders in the booming cell therapy field, has brought together one of the most prominent teams of scientists tackling cell therapy 2.0 highlighted by a quest to bridge a daunting tech gap that separates some profound advances in blood cancers with solid tumors. And today hes officially adding Hal Barron and GlaxoSmithKline as a major league collaborator which is pitching in a large portion of the $600 million hes raised in the past year to make that vision a reality.

Weve being staying stealth, Klausner tells me, then adding with a chuckle: and going back to stealth after this.

Cell therapy has a lot of challenges, notes Barron, the R&D chief at GSK, ticking off the resistance put up by solid tumors to cell therapies, the vein-to-vein time involved in taking immune cells out of patients, engineering them to attack cancer cells, and getting them back in, and more. Over the years Rick and I talked about how it would be wonderful to take that on as a mission.

Unlock this story instantly and join 61,800+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read the rest here:
A new player is taking the field in a push for a hemophilia A gene therapy, and it's a big one - Endpoints News

Scientists have discovered a new way to treat cystic fibrosis (CF) that involves delivering artificial proteins to patients lung cells to replace the faulty cystic fibrosis transmembrane conductance regulator (CFTR) protein.

The finding was reported in the study, Anion carriers as potential treatments for cystic fibrosis: transport in cystic fibrosis cells, and additivity to channel-targeting drugs, published recently in the journal Chemical Science.

CF is a genetic disorder caused by mutations in the CFTR gene, which provides instructions to make the CFTR protein.This protein works as a channel that transports in and out of cells molecules with a negative electrical charge (called anions), such as chloride, which have a direct impact on the regulation of water transport and the production of mucus.

In patients with CF, the transport of anions is impaired, leading to a buildup of fluid in the lungs and other organs.

One approach to restore anion transport to CF cells [utilizes] alternative pathways for transmembrane anion transport, including artificial anion carriers (anionophores), the researchers wrote.

The basic idea is to deliver these anionophores to patients lung cells, so that these artificial molecule transporters may replace the faulty CFTR protein, and restore the transport of water and salt in and out of cells, alleviating the symptoms of CF.

According to the researchers, these anionophores, unlike other types of targeted therapies that have been developed to correct specific defects in CFTR, may be used as a form of treatment for all CF patients, either alone or in combination with other CF therapies.

In their study, researchers from the University of Bristol in collaboration with investigators from the University of Southampton, both in the U.K., designed and tested 22 different anionophores.

Researchers discovered that four of these compounds (compound 11, 12, 15, and 19) were able to effectively transport anions in and out of lung cells cultured in a lab dish in a dose-dependent manner.

Moreover, they showed that all four compounds improved the transport of anions in cells that contained the F508 deletion, the most common CFTR mutation associated with CF, when used together with lumacaftor and ivacaftor, the active ingredients of two ofVertex Pharmaceuticals approved CF therapies, Orkambi and Kalydeco.

We also show that the compounds need not be toxic, which is an important issue, and that their activity can supplement the effects of recently introduced drugs, which help some CF patients through a different mechanism, Anthony Davis, from the University of Bristol and corresponding author of the study, said in a press release.

Overall, the results provide further evidence that anionophores, by themselves or together with other treatments that restore anion transport, offer a potential therapeutic strategy for CF, the researchers wrote.

Theres still a long way to go, but if the research proceeds as hoped it might lead to a genuinely effective and general treatment for CF patients over this timescale, Davis said.

Joana holds a MSc in Biology and a MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. She is currently finishing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that made up the lining of blood vessels found in the umbilical cord of newborns.

Total Posts: 336

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

See the original post:
Scientists Hope They Have Found New Form of Cystic Fibrosis Therapy - Cystic Fibrosis News Today

Hemophilia Gene therapy is introduction of healthier gene into the body of the patient which replaces the damaged gene. Due to the progress and technology advancement Hemophilia gene therapy is soon expected to be a possibility. Hemophilia is one disease which is expected to be a target for treatment with hemophilia gene therapy. People suffering from hemophilia have difficulty and lack in forming blood clots which brings them at hug risk of uncontrolled bleeding during minor injuries and internal bleeding into muscles and joints. There are no approved Hemophilia Gene therapy presently however the treatment involve injections which clot the proteins, these proteins are expensive and cost about 1 million per year. Manufacturers and scientists with continuous Research and development are making efforts for successful treatment of Hemophilia by Gene therapy. Patients suffering from hemophilia A has a mutation for factor VIII in the gene and patients suffering from hemophilia B have a mutation due to the absence of clotting factor IX. The final goal of hemophilia gene therapy is the restoration of a corrected gene for the rest of the life of the patient which is a challenging and yet not accomplished. Hemophilia gene therapy treatment has a low brink for success. The hemophilia gene therapy uses viruses as a vector however the problem is the vector is not large enough which can carry all the genes and the other problem occurs during the insertion of the vector as the vector is a virus there is a possibility that it can interfere with immune system and react to it. Moreover hemophilia gene therapy is more likely to interact with the immune system if the doses are increased. The scientists and the biopharmaceutical industries are trying their best in order to cure Hemophilia A and B by gene therapy.

Tentatively,Hemophilia Gene therapyMarkethas been segmented on the basis of product type.

On the basis of Indication, Hemophilia Gene therapy Market can be segmented as:

Request Sample Report@https://www.factmr.com/connectus/sample?flag=S&rep_id=3107

Global Hemophilia Gene therapy Market will witness advancement due to the rising population suffering from hemophilia. According to national institute of hemophilia approximately 20,000 people in U.S. and 400,000worldwide are suffering from hemophilia. The National hemophilia foundation is awarding grants to further support the research for Hemophilia Gene therapy which will in turn help in the treatment of hemophilia. The biopharmaceutical manufacturers and research centers are working together to understand the genetics of hemophilia and improve Hemophilia Gene therapy which could help in treatment of hemophilia in the future. Manufacturers such as Roche has recently acquired Spark Therapeutics for its long term investment hemophilia A gene therapy market. Also many drugs for hemophilia gene therapy are in clinical trials. The continuous investment and research by the manufacturers is expected to improve the hemophilia gene therapy market in the coming future. Also Hemophilia Gene therapy assures to address the unmet needs by one time administration which will further improve its severity. However the arrival of Hemophilia Gene therapy is a concern over its affordability and accessibility.

Geographically, global Hemophilia Gene therapy Market is split into regions viz. North America, Latin America, Middle East & Africa, Asia Pacific, Western Europe and Eastern Europe. North Americas Hemophilia Gene therapy Market is expected to grow because of evolution and progression in the technology and advancements to improve the patients health. However the willingness of payers and government to arrange funding or insurance coverage for Hemophilia Gene therapy is not well established. If the manufacturers that bring Hemophilia Gene therapy to the market have conventional and older hemophilia therapies within their product portfolio their consideration to offer gene therapy for low price may lack as the new technology would disrupt their present market.

Some of the major market members in the Global Hemophilia Gene therapy Market identified across the value chain includes: F. Hoffmann-La Roche AG, Pfizer Inc., BioMarin Pharmaceuticals, uniQure, Shire PLC, Sangamo Therapeutics, among others.

The report provides in-depth analysis of parent market trends, governing factors and macro-economic indicator and along with market attractiveness as per segments. Also the report is a compilation of qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report also outlines the qualitative impact of different market factors on market segments and geographies.

Request/View TOC@https://www.factmr.com/connectus/sample?flag=T&rep_id=3107

The report Haemophilia Gene therapy Market covers exhaustive analysis on:

Gene therapy Market Regional analysis includes:

Report Highlights:

Report Analysis@https://www.factmr.com/report/3107/hemophilia-gene-therapy-market

Shambhu Nath Jha

View all posts byShambhu Nath Jha

Read more:
Hemophilia Gene Therapy Market Segments and Key Trends 2018 to 2028 - My People Times

New York City, NY: Oct 09, 2019 Published via (Wired Release) The global Gene Therapy market is comprehensively researched and analyzed in the report by MarketResearch.Biz to help out market players to improve their business plans and ensure long-term success.

The study includes of 100+ market data Graphs & Figures, Gene Therapy Pie Chart, and Tables. The report has an in-depth analysis and is easy to understand. Currently, the Gene Therapy market is increasing its presence. The Research report shows a complete evaluation of the market and has ongoing growth factors, upcoming trends, facts, attentive opinions, and market data verified by the Gene Therapy industry. The report offers a forecast for global Gene Therapy Market till 2028.

Gene Therapy market report offers a comprehensive outlook of current trends and new product launch in the global Gene Therapy market. Featuring worldwide and regional data and over leading key players profiles, this report serves the ultimate guide to exploring opportunities in the Gene Therapy industry globally. The author of the report has used simple language and uncomplicated statistical figures that comprised thorough information and complete information on the global Gene Therapy market. The report provides market players with useful information and suggests result-oriented tactics to gain a competitive edge in the Gene Therapy market. This shows how distinct players are competing in the worldwide market and discusses strategies to distinguish themselves from other competitors.

For Detailed Insights and Better Understanding of Gene Therapy Market, Request Free Sample PDF Here: https://marketresearch.biz/report/gene-therapy-market/request-sample

Key highlights and crucial features of the report:

1) Which leading players are presently included in the report?

Here are the companies that are presently included in the report: Amgen Inc, NewLink Genetics Corp., Bluebird bio Inc, Kite Pharma Inc, Novartis, Transgene SA, Genethon, Spark Therapeutics Inc, GlaxoSmithKline PLC, Applied Genetic Technologies Corporation and Oxford BioMedica PLC.

** List of the companies stated above might differ in the final report dependent on a merger, name change, and other factors.

2) Can you list or add the latest firms as per client requirement?

Yes, we can add a new firm as per your requirement. The final confirmation regarding the same must be provided by the research team subject to the difficulty of the survey.

** Availability of information will be confirmed after research in the case of a privately held firm.

3) Which regions are covered in the report? Is it possible to list any specific country?

Currently, our research report provides special focus and attention on the following areas:

Europe, China, United States, Japan, India, and Central & South America, Southeast Asia.

** Instead Of the above countries if the client required any regional customize report we do provide. The final confirmation regarding the same must be provided by our research team.

4) Is it possible to include extra Market breakdown or segmentation in the report?

Yes, it is possible depending on the difficulty of the survey and availability of market data. However, a detailed sharing of your requirements with our research team is a must before providing final confirmation to the client.

** Deliverable time and quote might vary depending upon the requirements.

Have Any Query Or Specific Requirement? Feel Free To Ask Our Industry Experts: https://marketresearch.biz/report/gene-therapy-market/#inquiry

Segmentation Analysis:

By Vector: Viral vector, Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Non-viral vector, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection. By Gene Therapy: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth factors, Receptors, Other. By Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious disease, Other Diseases

So as to get a more intense view of the Gene Therapy market size, competitive scenario is offered. This includes revenue Gene Therapy market share (%) by major players and revenue (in Mn USD) by major companies. Moreover, a qualitative study is made towards Gene Therapy market product/service differences, concentration rate, development of future trends, and new entrants. The Gene Therapy industry overviews, SWOT analysis and business strategies of each vendor in the market give understanding about the Gene Therapy market forces and how those can be utilized to create future growth opportunities.

Production Analysis: SWOT analysis of Gene Therapy industry key players based on Strengths, Weaknesses, Challenges, Companys internal & external environments. , Market Opportunities and Risks. It also contains Production, Revenue, and product price and market shares of key players. That information are further subject to Manufacturing Base Distribution, Gene Therapy Production Area and Product Type. Major points like Competitive landscape and latest Trends, Industry Mergers & Acquisitions, Expansion which are crucial information to grow/establish a business is also comprised.

Browse More Insight Of Gene Therapy Market Research Report Enabled with Respective Tables and Figures at: https://marketresearch.biz/report/gene-therapy-market/

In this research, the years considered to predict the market size of Gene Therapy Market are as follows:-

History Year: 2013-2017

Base Year: 2018

Estimated Year: 2019

Forecast Year: 2019 to 2028

Detailed analysis, actual numbers, market size evaluation, and Gene Therapy business opportunities are available in the full report.

Thank you for reading this article, you can also get a separate customize chapter-wise section or region-wise report editions.

About Us:

MarketResearch.Biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. The company offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Contact Us:

Mr. Benni Johnson

Prudour Pvt. Ltd.

420 Lexington Avenue,

Suite 300 New York City, NY 10170,

United States

Tel: + 1-347-826-1876

Email ID: [emailprotected]

Website: https://marketresearch.biz/

This content has been distributed viaWiredReleasepress release distribution service. For press release service enquiry, please reach us at[emailprotected].

Continue reading here:
Gene Therapy Market 2028 Forecasts and Analysis with Top Key Players like Novartis, Kite Pharma, GlaxoSmithKline PLC - TheLoop21

New York City, NY: October 9, 2019- WorldGene Therapy MarketResearch Report is classified by key Gene Therapy manufacturers, regions, and various segmentation to offers all important details to the readers. A thorough analysis of Gene Therapy market based on product portfolio, applications, price, production processes included in Gene Therapy are calculated deeply. The market is hoped to have additional upcoming players which may lean to gigantic worldwide market development. Gene Therapy industry growth,scope, with Gene Therapy revenue are specifiy in this report.

Detailed study of Gene Therapy market competition, advancement, Gene Therapy development opportunities and factors restraining the market growth are study in detail. All the elementary market information like Gene Therapy consumer volume, market size, demand/supply analysis, and Gene Therapy gross margin study are included in this report. The changing competitive environment will lead to accretion of revenue in Gene Therapy market.

Worldwide Gene Therapy study will offers as a worthwhile guide for studying business opportunities and building the strategic business judgment which will gives benefit in Gene Therapy. The latest Gene Therapy trend and updated marketing strategies will foreseen the Gene Therapy market presentation in upcoming years.

Download Sample Copy of Gene Therapy Market Report Study 2019-2028 At:https://marketresearch.biz/report/gene-therapy-market/request-sample

This information relevant to innovations proceed,technical advancement, in Gene Therapy, press release, Gene Therapy marketing strategies are expanded in this report. The report also manage Gene Therapy market inspection on a global and regional basis to provide worldwide market projection and market share for the upcoming period 2019 to 2028.

Purview of the Gene Therapy Market Report:

The foreseen Gene Therapy market trends, industry development, sales margin estimated over the forecast period are included in this report. The process containing in Gene Therapy manufacturing, end users, sellers, buyers, manufacturers are analysed deeply in this report.

Key developments, supply chain static of Gene Therapy, innovations will guide the market players to build up the strategies for business. Obtaining crucial Gene Therapy information and structured it in a separate way will help enhnaced the decisions.

Global Gene Therapy Market Classification:

This report illustrate the competitive landscape sight of all the key players depend on their company profile, Gene Therapy sales profit, development stature, Gene Therapy import/export scheme and consumption rate. The Gene Therapy improvement and market revenue are provided for each and every region, manufacturer and Gene Therapy application of product. The leading manufacturers of global Gene Therapy market contains Amgen Inc, Oxford BioMedica PLC, Genethon, Applied Genetic Technologies Corporation, GlaxoSmithKline PLC, NewLink Genetics Corp., Spark Therapeutics Inc, Transgene SA, Kite Pharma Inc, Bluebird bio Inc and Novartis.

The Gene Therapy manufacturing regions like Asia-Pacific, Canada, United States, Italy, South America, Africa, Japan, Mexico, Brazil, Southeast Asia, UK, Australia, Germany, Russia, Europe, Middle East & Africa, France, India,North America, Korea, and China are included in this Gene Therapy report. Gene Therapy industry scope and statistical data related to past, current and future Gene Therapy market are analysed in this report study.

Eccentricity Of The Global Gene Therapy Market Report:

Study of latest and future Gene Therapy industry trends will give boost to growth opportunities. The upcoming information relevant to market share, revenue, and growth will beneficial while taking the business decisions. The separate study depend on regions, and various segments will provides all the minuscule details to the readers. Growth endorsement, study of company profiles of Gene Therapy major manufacturers and strategies endorse by major players will propel business vision. Usefulness of investment anaylsis, market existence, and upcoming Gene Therapy sections will determine the market scope in forecasting years.

Enquire about the report, talk with our specialist at:https://marketresearch.biz/report/gene-therapy-market/#inquiry

TOC of Gene Therapy Report:

Part 1 of the report offers data related to Gene Therapy product scope, industry outlook, growth opportunities, challenges to the Gene Therapy market growth and major propeling forces.

Part 2 provides overall detailing related to key Gene Therapy manufacturers, their sales revenue, and product cost structure forecast over 2019-2028.

Part 3 lists the competitive sight of the Gene Therapy market depend on the company profile, volume and market share forecast from 2019-2028.

Part 4 analysis the major regions giving contribution to the market growth, their sales margin, size and leading manufacturing countries includes with these regions.

Part 5,6 gives details related to Gene Therapy industry size and share of each manufacturers existing within the region, trends, Gene Therapy scope, and application, forecast from 2019-2028.

Part 7,8 serves global market study based on various segments, Gene Therapy sales volume, forecast from 2019-2028.

Part 9 provides the futuristic market data relevant to Gene Therapy like the projected development, revenue share, market scope, emerging regions and the growth prospects of the industry.

Part 10 covers the study of Gene Therapy marketing channels, vendors, traders and finally beneficial research conclusions are served.

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us atcontact@wiredrelease.com.

Excerpt from:
Gene Therapy Market Growth Prospects, Traders, Opportunities with Growth Factor By 2028 - Healthcare News

Zion Market Research published a new 110+ pages industry researchGene Therapy Market: by Type (Somatic Cell Gene Therapy and Germ Cell Gene Therapy) and by Application (Genetic Disorders, Cancer, Cardiovascular Disease, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 20172024.

TheGlobal Gene Therapy Market Is Expected To Reach Around USD 2,269 Million By 2024complete outline is crystal clear penned down in the GlobalGene Therapy Marketresearch report such that not only an unskilled individual but also a professional can easily extrapolate the entire Gene Therapy Market within a few seconds.The research study covers research data which makes the document a handy resource for managers, analysts, industry experts, and other key people get ready-to-access and self-analyzed study along with TOC, graphs and tables to help understand the market size, share, trends, growth drivers and market opportunities and challenges.

Download FREE PDF Sample Brochure for more Industry Insights @CLICK HERE NOW

The Gene Therapy Market research report covers major industry player profiles that include:

UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension Therapeutics

This report employs the SWOT analysis technique for the assessment of the development of the most remarkable market players. It additionally considers the latest upgrades while assessing the development of leading market players. Moreover, in the global Gene Therapy Market report, the key product categories of the global Gene Therapy Market are included. The report similarly demonstrates supportive data related to the dominant players in the market, for instance, product offerings, revenue, segmentation, and business synopsis. The global Gene Therapy Market is as well analyzed on the basis of numerous regions.

Download FREE PDF Sample for more Insights@CLICK HERE NOW

Global Gene Therapy Market: Regional Analysis

To understand the competitive landscape in the market, an analysis of Porters five forces model for the market has also been included. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness. This report is prepared using data sourced from in-house databases, secondary and primary research team of industry experts.

Browse Press Release@CLICK HERE NOW

The report answers important questions that companies may have when operating in the Global Gene Therapy Market. Some of the questions are given below:

What is the current CAGR of the Global Gene Therapy Market?

Which product is expected to show the highest market growth?

Which application is projected to gain a lions share of the Global Gene Therapy Market?

Which region is foretold to create the most number of opportunities in the Global Gene Therapy Market?

Will there be any changes in market competition during the forecast period?

Which are the top players currently operating in the global market?

How will the market situation change in the coming years?

What are the common business tactics adopted by players?

What is the growth outlook of the Global Gene Therapy Market?

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia.

Sorry! The Author has not filled his profile.

Read the original post:
Gene Therapy Market to exceed USD 2269 Million By 2024 - The Industry Today News

Cancer Gene Therapy Market SWOT Analysis And Forecast 2024

The Cancer Gene Therapy Market report has been added to Qurate Business Intelligence offering. The global Cancer Gene Therapy Market report offers the important data to help the firms cope up with the knowledge gap due to the advancements in the industry and effectively utilize the opportunities that present itself into the ever-changing market.

Cancer Gene Therapy Market highlights the information about the dominant players industries and market, technologies, and abilities over the trends and the developments of the industries. After deep research and analysis by the experts, they also disclosed the data about the strong contenders contributing in the market growth and expansion and challenging one another in terms of demand, supply, production, value estimation, revenue, and sales.

The latest report offers wide-ranging coverage of several important industry verticals along with key market players. It as well offers consistency on the part of analysis or estimation across a range of coverage areas and geographies.

Request Sample of Cancer Gene Therapy Market Report: https://www.qurateresearch.com/report/sample/HnM/2019-2024-global-and-regional-cancer-gene-therapy-industry/QBI-HNY-HnM-487185/

Major Key players of Cancer Gene Therapy Market:

Adaptimmune, GlaxoSmithKline, Bluebird bio, Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, OncoGenex Pharmaceuticals, Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancell, Celgene, Epeius Biotechnologies, Introgen Therapeutics, Ziopharm Oncology, Shenzhen SiBiono GeneTech, Altor Bioscience,

Type

Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

Application

Hospitals, Diagnostics Centers, Research Institutes

Cancer Gene Therapy MarketPromising Regions & Countries Mentioned In The Cancer Gene Therapy Market Report: North America (U.S and Canada and the rest of North America)Europe (Germany, France, Italy and Rest of Europe)Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

Click here to get [emailprotected] https://www.qurateresearch.com/report/discount/HnM/2019-2024-global-and-regional-cancer-gene-therapy-industry/QBI-HNY-HnM-487185/

AbstractThe report covers the forecast and analysis for the Cancer Gene Therapy Market on a global and regional level.The report includes the positive and the negative factors that are influencing the growth of the market.The revenue generated by the prominent industry players has been analyzed in the report.The market numbers have been calculated using top-down and the bottom-up approaches.The Cancer Gene Therapy Market has been analyzed using S.T.E.E.P.L.E. Analysis (Social, Technological, Environmental, Economical, Political, Legal, Ethical) .The market is segmented on the basis of Cancer Gene Therapy Market type, software type, service type, solution type, and application type, which in turn is bifurcated on a regional level as well.All the segments have been evaluated based on the present and the future trends.The report deals with in-depth quantitative and qualitative analyses of the Cancer Gene Therapy Market.The report includes the detailed company profiles of the prominent market players.

Inquire more or share questions if any before the purchase on this report @ https://www.qurateresearch.com/report/enquiry/HnM/2019-2024-global-and-regional-cancer-gene-therapy-industry/QBI-HNY-HnM-487185/

The global Cancer Gene Therapy Market report conveys the information regarding the prcised escalation or decline in market growth due to several key factors. The analysts, using various analytical methodologies such as SWOT analysis, S.T.E.E.P.L.E. Analysis, etc. among others to generate the precise forecast belonging to the growth rate and upcoming opportunities in the market growth at the global level. The global Cancer Gene Therapy Market report represents the complete information of the market in an eye-catching and easily understandable way with examples, figures, graphs, and flowcharts.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Continued here:
Cancer Gene Therapy Market 2019 In-Depth Analysis of Industry Share, Size, Growth Outlook up to 2024 - Space Market Research

DUBLIN, Oct. 10, 2019 /PRNewswire/ -- The "Global DNA Read, Write and Edit Market" report has been added to ResearchAndMarkets.com's offering.

The scope of the report includes DNA read, write and edit technologies, applications, industries, initiatives, patents, and companies. The markets for read, write and edit products and services are given for 2017, 2018, 2019 (estimated) and 2024 (forecast).

This report reviews the main read, write and edit technologies and explains why genetic variation is important in clinical testing and disease. It then discusses significant large-scale research initiatives that impact read, write and edit applications. Of particular interest is a discussion of population-scale sequencing projects throughout the world, and their likely impact. The main market driving forces for read, write and edit products and services are listed and discussed.

The report quantifies each of the main market segments. The read (sequencing) market is quantified by delivered format, including sequencing workflow products (sample preparation kits and reagents, sequencing instruments and consumables, and informatics) and sequencing services (clinical diagnostics and sequencing services to applied market customers).

The sequencing workflow products market is quantified by type, that is, DNA isolation and extraction; target enrichment; library preparation; and informatics/ecosystems. The sequencing instruments and consumables market is given by platform (Sanger, NGS, and 3GS).

The sequencing services market is analyzed by end-user application (applied, clinical, and R&D). Within sequencing services, the applied market is analyzed by end-user application (agriculture, biopharma, consumer, microbiology, population-scale genomics, synthetic biology and other).

Also within sequencing services, the clinical market is analyzed and quantified by disease category (cardiovascular, clinical microbiology and infectious diseases, Mendelian disorders, metabolic/immune disorders, neurology, oncology, reproductive health, and transplant medicine).

The DNA write (synthesis) market is quantified by product type (oligonucleotides, synthetic biology parts, genes, and RNA therapeutics). The oligonucleotide market is analyzed by application (gene editing, sequencing, PCR, FISH, microarray, gene synthesis and other). The gene market is quantified by gene type (standardized, value-added). Finally, the RNA therapeutics market is quantified by platform (RNA interference, antisense oligos, micro RNA modulation, and mRNA) and by disease category (cancer, hematology, musculoskeletal, neurology, and rare diseases).

The DNA edit (gene editing) market is quantified by application (agriculture, biopharma, diagnostics, and therapeutics); editing platform (CRISPR, meganuclease, TALEN, ZFN). The gene-editing agriculture market is analyzed by product type (crop/seeds, livestock). The gene-editing biotechnology market is analyzed by product type (kits and reagents, cell line engineering, animal models and services). The gene-editing therapeutics market is analyzed by disease category (eye and rare diseases).

Specific geographic markets discussed include North America, Europe, Asia-Pacific, and the rest of the world (ROW).

Industry sectors analyzed include next-generation sequencing; long-read sequencing; DNA synthesis; RNA therapies; and gene editing.

More than 320 companies in the read, write and edit industry are profiled in this report.

The author also provides a summary of more than 180 of the main industry acquisitions and strategic alliances that took place from January 2018 through June 2019, including key alliance trends.

Market Summary

The DNA read, write and edit industry is at the beginning stages of its growth story; penetration of the key markets is still at an early stage. The data indicates that there is a significant future upside for sequencing across research, metagenomics, agriculture, synthetic biology, and clinical applications, among others.

The situation is similar for DNA writing and editing technologies, with clinical therapeutic applications, in particular, providing an enormous total available future market that is yet to be significantly penetrated. Major successes in this industry include the adoption of next-generation sequencing (NGS) for noninvasive prenatal testing; enabling the roles of synthetic DNA oligonucleotides and genes in the rise of the synthetic biology industry; and rapid adoption of CRISPR gene editing by research institutions and biopharma industries.

There is increasing interplay among the three DNA technology platforms, giving rise to innovative corporate strategies. For example, Arbor Biotechnologies employs sequencing, gene synthesis, and artificial intelligence to perform high-throughput discovery of biomolecules, including new CRISPR proteins.

Report Scope

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Overview

Chapter 4 Technology Background

Chapter 5 DNA Read, Write and Edit Initiatives

Chapter 6 DNA Read, Write and Edit Applications

Chapter 7 DNA Read, Write and Edit Industries

Chapter 8 Acquisitions and Strategic Alliances

Chapter 9 DNA Read, Write and Edit Markets

Chapter 10 Patents

Chapter 11 Nucleic Acid Read, Write and Edit Company Profiles

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/7jlxd8

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original here:
Analysis on the Global DNA Read, Write & Edit Market, 2017-2019 and Forecast to 2024 - PRNewswire

Zion Market Research published a research report containing 110+ pages titled Gene Therapy Market: by Type (Somatic Cell Gene Therapy and Germ Cell Gene Therapy) and by Application (Genetic Disorders, Cancer, Cardiovascular Disease, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 20172024 in its research offering. This report is well crafted with a combination of the crucial data associated with the worldwide market, along with key factors liable for the demand for its services and merchandise. The report highlights the newest technological developments and new launches that assist our customers to set up their future-based potential products, make wise business selections to meet the projected demand ratio.

This report is an excellent presentation of critical dynamics, regional growth, competition, and other important aspects of the global Gene Therapy Market. This report will provide accurate market figures and statistics that include market CAGR, revenue, volume, consumption, production, market shares, price, and gross margin. Each regional market analysis in the report is carefully analyzed to explore key opportunities and business prospects they are expected to offer in the near future. This report also includes major market players in the global Gene Therapy market on the basis of various factors including their past market performance, market size & share, by product analysis, distribution channels, marketing strategies, etc. This equips players with crucial information and data to improve their business tactics and ensure a strong foothold in the global Gene Therapy market.

To Know More, Request Sample Report @ http://www.zionmarketresearch.com/sample/gene-therapy-market

How this report helps you?

Major Company Profiles Included in This Report:

UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension Therapeutics

Key Highlights of TOC

Industry Overview: This starts with a product overview and scope of the global Gene Therapy market. It also gives consumption and production growth rate comparisons by application and product respectively. It also includes a glimpse of the regional study and market size analysis for the review for the forecasted period.

Major Company Profiles: Each company profiled in the report is assessed for its market growth keeping in view vital factors such as price, gross margin, revenue, production, markets served, main business, product specifications, applications, and introduction, areas served, and production sites.

Market Dynamics: The readers are provided with a comprehensive analysis of market challenges, demand, market influence factors, growth drivers & restraints, global opportunities, and trends.

Market Forecast: The research report will provide forecast by application, price, revenue, and production forecast by product, consumption forecast by region, production forecast by region, and production and revenue forecast.

Report Methodology and Data Source Used: This report includes the publishers disclaimer, list of authors, major primary and secondary sources, and research approach.

Request for a Report PDF Brochure for Brief Analysis Summary @ http://www.zionmarketresearch.com/requestbrochure/gene-therapy-market

The Gene Therapy market report keenly emphasizes on industrial affairs and developments, approaching policy alterations and opportunities within the market. The regional development methods and its predictions are explained in every key point that specifies the general performance and issues in key regions such as the US, Asia Pacific, Middle East, and Europe. Various aspects such as production capability, demand, product value, material parameters and specifications, distribution chain and provision, profit and loss, are explained comprehensively in the Gene Therapy market report.

The report hands in-depth segmentation of the worldwide market based on supported technology, product type, application, and numerous processes and systems. The report attains economical competitive analysis, business trends within the market, and alternative key characteristics of the worldwide Gene Therapy market. Our experts have genuinely concatenated the Gene Therapy market report by alluding the lists and figures, primary sources, with an intention to boost the understanding of the associated procedural terms and conditions.

Some of the major regions covered in this Gene Therapy Market report:

Read More Report Details @ http://www.zionmarketresearch.com/report/gene-therapy-market

The Gene Therapy market report includes the leading advancements and technological up-gradation that engages the user to inhabit with fine business selections, define their future-based priority growth plans, and to implement the necessary actions. The global Gene Therapy market report also offers a detailed summary of key players and their manufacturing procedure with statistical data and a profound analysis of the products, contribution, and revenue.

Every information given in the report is sourced and verified by our expert team and is collated with precision. To give a broad overview of the current global market trends and strategies led by key businesses, we present the information in a graphical format such as graphs, pie-charts with a superior illustration.

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research

244 Fifth Avenue, Suite N202New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll-Free No.1-855-465-4651

Email: [emailprotected]

Website: http://www.zionmarketresearch.com

Sorry! The Author has not filled his profile.

Continue reading here:
Global Gene Therapy Market Revenue Will Grow Over USD 2269 Million By 2024 - Industry PressRelease

Heres our recent analysis on Global Gene Therapy for Age-related Macular Degeneration Market research report 2019-2025 which primarily explains the crucial growth factors of the market that are impacting the Gene Therapy for Age-related Macular Degeneration industry along with the upcoming possibilities that are expected to influence the Gene Therapy for Age-related Macular Degeneration market during the forecast session between 2019 to 2025. In this study, the global Gene Therapy for Age-related Macular Degeneration market is evaluated through distinct industry elements such as restraints, opportunities, and drivers to help the users to have a better understanding about the fundamental overview of the Gene Therapy for Age-related Macular Degeneration market.

Request for sample copy of the report: https://spiremarketresearch.com/report/global-gene-therapy-agerelated-macular-degeneration-market-2472#request-sample

In 2019, the global Gene Therapy for Age-related Macular Degeneration market size is valued at million US$ and it will be anticipated to gain million US$ by the end of the year 2025, which is boosting at a CAGR during the predicted period. While, in the Chinese continent, the Gene Therapy for Age-related Macular Degeneration market size is estimated at xx million US$ and it will grow about xx million US$ in 2025, with a CAGR of xx % from 2019-2025. The research report evaluates 2018 as the base year and 2019-2025 has been determined as the forecast timespan to estimate the Gene Therapy for Age-related Macular Degeneration market size.

Leading Players of the Gene Therapy for Age-related Macular Degeneration market are:

RetroSense TherapeuticsREGENXBIOAGTC

Gene Therapy for Age-related Macular Degeneration Market segmented by product types:

SubretinalIntravitrealUnspecified

Applications can be divided as:

MonotherapyCombination Therapy

Inquiry before buying the Gene Therapy for Age-related Macular Degeneration market report: https://spiremarketresearch.com/report/global-gene-therapy-agerelated-macular-degeneration-market-2472#inquiry-for-buying

The research study accumulates the global Gene Therapy for Age-related Macular Degeneration market size on the basis of major topographical regions like Unites States, China and other zones including Japan, India, Korea, and Southeast Asia. Furthermore, the report firmly explains plenty of key factors including revenue share, Gene Therapy for Age-related Macular Degeneration market size, sales volume, and growth rate of each company. It also describes the statistical information regarding the revenue, Gene Therapy for Age-related Macular Degeneration market share and sales by regions, types, and applications. Meanwhile, it represents historical data from 2014 to 2019 and forecast to 2025.

This report analyzes essential details like price, production volume, market share, growth rate, and Gene Therapy for Age-related Macular Degeneration market value for the key players and collects informative data from 2014 to 2019 for the leading companies in USA, China, and European Union. Therefore, this study offers a brief introduction of the worldwide Gene Therapy for Age-related Macular Degeneration market along with in-depth evaluations for the revenue from 2019 to 2026 and determines market dimensions with respect to the provided aspects. The current industry vendors, stakeholders, and consultants are also included in the Gene Therapy for Age-related Macular Degeneration market in order to articulate the several paths and also implements gathered choices.

Excerpt from:
Gene Therapy for Age-related Macular Degeneration Market Growth Analysis Reports by Companies RetroSense Therapeutics, REGENXBIO - The Chicago...

Zion Market Researchpublished a new industry research reportGlobal Gene Therapy Market Is Expected To Reach Around USD 2,269 Million By 2024is all around created with a blend of the significant information related with overall Gene Therapy Market, alongside key components obligated for the interest for its administrations and product.(Sample Copy Here)Gene Therapy Marketreport also provide a thorough understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, challenges, and opportunities in the Market to offer worthwhile insights and current scenario for making right decision. The report covers the prominent players in the market with detailed SWOT analysis, financial overview, and key developments of the products/services from the past three years. Moreover, the report also offers a 360 outlook of the market through the competitive landscape of the global industry player and helps the companies to garnerGene Therapy Marketrevenue by understanding the strategic growth approaches.

Request For Free Sample ofGene Therapy MarketReport:www.zionmarketresearch.com/sample/gene-therapy-market

Table of Contents

Get Free Brochure ofGene Therapy MarketReport:www.zionmarketresearch.com/requestbrochure/gene-therapy-market

The Gene Therapy Market report includes the leading advancements and technological up-gradation that engages the user to inhabit with fine business selections, define their future-based priority growth plans, and to implement the necessary actions. The global Gene Therapy Market report also offers a detailed summary of key players and their manufacturing procedure with statistical data and profound analysis of the products, contribution, and revenue.

This report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers. Second on basis of segments by manufacturers, this report focuses on the sales, price of each type, average price ofGene Therapy Market, revenue and market share, for key manufacturers.

Browse Press Release@www.zionmarketresearch.com/news/gene-therapy-market

This report focuses on Time and Expense Management System volume and value at global level, regional level and company level. From a global perspective, this report represents overall Time and Expense Management System market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

Available Array of Customizations:

The classification of the global Gene Therapy Market is done based on the product type, segments, and end-users. The report provides an analysis of each segment together with the prediction of their development in the upcoming period. Additionally, the latest research report studies various segments of the global Gene Therapy Market in the anticipated period.

Also, Research Report Examines:

Lastly, with a team of vivacious industry professionals, we offer our clients with high-value market research that, in turn, would aid them to decipher new market avenues together with new strategies to take hold of the market share.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia

Browse for more Research Reports:fnfresearch.com

Sorry! The Author has not filled his profile.

View original post here:
Global Gene Therapy Market to Accumulate Revenues Worth US $2269 Million By 2024 - Market News Network

Introduction

Mereo BioPharma (MREO) is a British small-cap ($62M) biopharma developing therapeutics for rare disorders as well as endocrine and oncological diseases. MREO has a diverse pipeline including MPH-966 (alvelestat), BCT-197 (acumapimod), and OMP-305B83 (navicixizumab) for alpha-1 antitrypsin deficiency, chronic obstructive pulmonary disease, and ovarian cancer, respectively. The focus of this article is BGS-649 (leflutrozole), a drug asset licensed from Novartis (NVS) that is in clinical development for treating hypogonadotropic hypogonadism (Hypo-H).

Hypogonadism is a medical condition characterized by a deficiency in testosterone, the primary male circulating sex hormone synthesized in the gonads. Hypogonadism can present itself during fetal development, before puberty or during adulthood. Testosterone is important in the development and maturation of reproductive tissues. Symptomatic events of this disorder are decreased libido, impaired erectile function, muscle weakness, increased adiposity, depressed mood, and decreased vitality.

Hypogonadism can be triggered by a primary testicular disorder (hypergonadotropic; Hyper-H) whereas hypogonadotropic hypogonadism (Hypo-H) is a consequence of congenital or acquired diseases that affect the hypothalamus and/or the pituitary gland.

The hypothalamus (i.e. brain), pituitary (i.e. endocrine), and gonadal (i.e. reproductive) glands are all often known as hypothalamic-pituitary-gonadal axis because they all act in concert in the development and regulation of the reproductive and immune systems. Any alteration in this axis induces changes in the hormones produced by each gland that can affect their various local and systemic effects on the body. Hypo-H is frequently reported in metabolic disorders such as obesity, type 2 diabetes, and metabolic syndrome.

Men who present with Hyper-H do not respond to hormone replacement medication because the disorder is caused by primary testicular failure. Testosterone hormone replacement is the mainstay treatment for Hypo-H to normalize testosterone levels and restore fertility. Alternative options include gonadotropin therapy regimen to induce endogenous testosterone, aromatase inhibitors, and selective estrogen receptor modulators.

BGS-649 (leflutrozole) is a novel once-weekly oral aromatase inhibitor in clinical development as first-line therapy for the treatment of Hypo-H in obese men. The thesis is that BGS-649 normalizes testosterone levels by inhibiting aromatase and is, therefore, expected to improve the related conditions. The premise is that lower levels of testosterone in obese men with Hypo-H is driven by high levels of the aromatase enzyme in fat tissue which irreversibly converts testosterone into estradiol. Aromatase inhibitors are widely used therapeutically in breast cancer.

Clinical Data: A Phase 2b clinical trial of BGS-649 in 271 patients with Hypo-H achieved its primary clinical endpoint of total testosterone normalization:

in over 75% of subjects after 24 weeks of treatment, and in at least 90% of patients after 24 weeks at the two highest doses. All three doses met all secondary endpoints, including the improvement of testosterone luteinizing hormone (LH.) and follicle stimulating hormone (FSH.) levels. The exploratory endpoint of improvement in total motile sperm count was also met.

A safety extension study completed in 143 patients successfully demonstrated that none of the doses of BGS-649 met the lower bound (95% confidence interval) of the pre-specified safety criterion of a greater than 3% reduction in lumbar spine bone mineral density (BMD) after 48 weeks of treatment. The extension study also demonstrated normalization of testosterone in more than 90% of the patients at all three doses and maintenance of the effects on LH and FSH.

Individuals with Hypo-H lack or have low levels of gonadotropin-releasing hormone (GnRH.). GnRH is a peptide hormone secreted from the hypothalamus and stimulates gonadotropic cells in the anterior pituitary gland to release LH and FSH for normal gonad function including testosterone production by the testes. The observation that BGS-649 therapy was associated with normal FSH and LH levels in the Phase 2b study could suggest these patients also had GnRH levels normalized or elevated.

The prevalence of Hypo-H was estimated to be 1:10,000 to 1:86,000 individuals 20 years ago - meaning the prevalence could be higher due to increasing rates of obesity.

Upcoming catalytic events are:

Setrusumab for Osteogenesis Imperfecta (OI.)

12-month data from Phase 2b ASTEROID study in adult OI patients expected in Q4 2019. In May 2019, Mereo reported positive 6-month interim data from the fully-enrolled ASTEROID study. These data were accepted for a late-breaking oral presentation at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL, USA. The Company expects to report 12-month topline data from the blinded portion of the study in Q4 2019. There are currently no FDA or EMA-approved treatments for OI.

Pivotal pediatric study ready in the EU and Canada. In addition to evaluating setrusumab in adult OI patients, Mereo's Paediatric Investigation Plan (PIP) has been approved by the EMA and a study design has been agreed for a pivotal registration trial in children. Mereo is also exploring an extension of the planned pivotal study into the U.S.

Alvelestat for Severe Alpha-1 Antitrypsin Deficiency (AATD.)

Enrollment continuing for the Phase 2 proof-of-concept study in severe AATD patients with topline data expected in mid-2020. If the results are positive, Mereo intends to commence a pivotal trial in the EU and the U.S. in AATD as soon as possible thereafter.

Investigator-sponsored clinical studies underway in AATD and also in bronchiolitis obliterans syndrome (BOS) as a result of graft-versus-host disease (GvHD) in patients undergoing hematopoietic stem cell transplantation (HSCT). BOS is an orphan disease characterized by inflammatory obstruction of the lung's tiniest airways and is the primary cause of death in patients who receive lung transplants. Based on the preliminary clinical data to-date, Mereo intends to investigate the use of alvelestat to treat patients with BOS following a lung transplant.

Partnering Discussions Continue for Broad Portfolio of Clinical-Stage Programs

Leflutrozole for Hypogonadotropic Hypogonadism .. Following the positive Phase 2b and six-month extension data reported in 2018, earlier this year Mereo held an advisory board to consider the future development strategy for leflutrozole, with a focus on the positive effects on semen parameters. Mereo has decided that future product development will focus on male fertility.

Acumapimod for Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) is Phase 3-ready following a successful Type B End of Phase 2 meeting with the FDA and agreed outline for a pivotal Phase 3 clinical trial program. Recently, a positive Scientific Advice Working Party (SAWP.) also took place with the EMA.

Navicixizumab for Advanced Platinum-Resistant Ovarian Cancer. In July 2019, Mereo held a successful Type B End of Phase 1 meeting with the FDA regarding a potential pathway for accelerated approval for navicixizumab for the treatment of patients with advanced ovarian cancer. Mereo and the FDA discussed, and agreed in principle, an outline for the design of a Phase 2 clinical trial that could potentially support the accelerated approval of navicixizumab in patients with ovarian cancer (including peritoneal or fallopian tube cancer) who have become resistant to prior therapies.

Etigilimab for Advanced Solid Tumors. Etigilimab has completed a Phase 1a/b trial of etigilimab, administered as either a single-agent or in combination with nivolumab, in patients with advanced or metastatic solid tumors.

The biggest risk is the low cash reserve. As highlighted above, MREO is seeking partnership agreements for some of its clinical programs. Partnership agreements would provide the financial stability needed to advance its clinical pipeline.

At the end of Q2/2019, it reported cash, cash equivalents, and short-term investments of $45.06M (after conversion from pounds sterling). Institutional ownership currently stands at 1.88%, with 43 institutional holders accounting for 1,805,180 total shares. Analysts recommend a buy with an average price target of $7.20.

CEO Dr. Denise Scots-Knight on the future:

Our team remains focused on advancing discussions with potential partners to help us further realize the value of these assets and we look forward to updating you regarding these discussions in the future. In addition to the progress have highlighted regarding our development programs, we also continue the build out of our senior Management Team and board of directors to ensure that we have the necessary expertise and are well positioned as our programs continue to advance.

Thanks for reading. While I occasionally cover companies like this, my focus remains investment opportunities in liver therapeutics, specifically NASH and Cholestatic liver diseases, which are exclusive to members of my private investing community, Liver Therapy Forum Marketplace.

As a Ph.D. trained liver biomedical scientist & Scientific Consultant, I provide:

Novel mechanistic insights and "updating thesis" highlighting promising drug candidates.

Exclusive access to full-length in-depth research analytical articles, KOL interviews, newsletters/digests, and Q & A chat board.

Actionable events to minimize risks and grow your investments.

Knowledge and wisdom required to understand the diverse and complex NASH therapeutics landscape.

Sign-up today to grow your investments!

Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in MREO over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: As always, my articles are meant to facilitate your understanding. Readers are expected to form their own trading plan, do their own research and take responsibility for their own actions. Investing in common stock can result in partial or total loss of capital. Please implement due diligence and invest wisely.

Originally posted here:
Mereo BioPharma And Leflutrozole In Hypogonadotropic Hypogonadism - Seeking Alpha

Hypogonadism is defined as hormonal disorder in which the glands (gonads & ovaries) produce little or no hormones causing its deficiency in the body. Hypogonadism in males refers to deficiency of testosterone due to dysfunction of either of the testes. Female hypogonadism refers to deficiency of estrogen or progesterone due to reduced activity of the ovaries. Hypogonadism is classified into two types: primary hypogonadism (testicular failure) and central hypogonadism (hypothalamic-pituitary axis dysfunction). Other major causes of hypogonadism include autoimmune disorder, genetic disorder, severe infections, and liver and kidney diseases. Generally, hormone and imaging tests are used to diagnose hypogonadism.

According to the Boston University School of Medicine, around 4 million to 5 million men in the U.S. were affected with hypogonadism in 2003. The incidence of hypogonadism in men aged between 40 years and 69 years in the country is around 481,000 new cases per year. According to the European Male Aging Study, the prevalence of late onset hypogonadism in men aged between 40 and 79 was 2.1% in 2016. Studies suggest that hypogonadism in adult men is often underdiagnosed and undertreated and only 5%. According to the Urology Care Foundation, hypogonadism is a chronic condition which would require lifelong treatment. The treatment for hypogonadism depends on the cause and concern about fertility and includes treatment such as hormone replacement therapy or assisted reproduction.

Men with heart disease, HIV, COPD, or renal disease have high prevalence of hypogonadism. Factors such as rising prevalence of type 2 diabetes and obesity further increase the incidence of hypogonadism. Growth of the global hypogonadism treatment market is attributed to rise in geriatric population, increase in infertility, and improved diagnosis. However, growing concerns about the potential side effects, availability of generic drugs, and preference for other natural hormonal boosters and supplements are likely to hamper the growth of the hypogonadism treatment market. Increasing awareness, awaiting approvals for new generation drugs in pipeline, and technological advancements present significant opportunities in the hypogonadism treatment market.

The primary treatment option for hypogonadism is hormone replacement therapy. Based on product type, the market has been classified into testosterone replacement therapy, estrogen therapy, and progesterone therapy. Testosterone replacement therapy is the fastest growing segment as hypogonadism is more prevalent in men. The segment is expected to hold major share of the global market during the forecast period.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/hypogonadism-treatment-market.html

In terms of mode of administration, the hypogonadism treatment market has been broadly classified into transdermal patch, topical gel, buccal tablets, implantable pellet, intramuscular injections, and oral tablets. Transdermal patch followed by topical gels are anticipated to be the fastest growing segments as these provide steady route of administration and are easily modifiable over a short period of time. The oral and buccal tablets segments are anticipated to experience sluggish growth during the forecast period due to high side effects and liver diseases.

Based on the distribution channel they are segmented into hospital pharmacies, retail pharmacies and others. The major market share for the hypogonadism treatment market is for the retail pharmacies segment and is anticipated to rule the market during the forecast period as continuous long term treatment is required for the hypogonadism patient.

In terms of region, the global hypogonadism treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest market for hypogonadism treatment, accounting for more than half of the market share due to the factors such as increased adoption of newer highly advanced products, rising awareness about hormonal disorder including various treatment options available, and advancing health care infrastructure. However, Asia Pacific is anticipated to be the fastest growing market during the forecast period due to increasing urbanization and rise in the patient population.

Key players in the global hypogonadism treatment market are Bayer AG, Abbott Laboratories, Inc., Merck Serono, Sanofi, Merck & Co., Inc., Actavis, Inc., AbbVie Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Endo International plc, Ferring Holding S.A., and Laboratoires Genevrier.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=30392&source=atm

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=30392&source=atm

See original here:
Hypogonadism Treatment Market to Witness an Outstanding Growth by 2017 2025 - Space Market Research

Patent Expiry Blow Dealt to TRT Market Could be Softened by Growing Prevalence of Hypogonadism

A wide range of testosterone replacement therapy (TRT) products containing different active ingredients have been made available by a large number of both global and local manufacturers. With various studies estimating the number of men affected by hypogonadism (testosterone deficiency) at 30% worldwide, the demand for TRT is poised to increase gradually in the years ahead. The condition primarily affects men aged between 40 and 79 years, making this demographic a key target segment for market players.

Obtain Report Details @https://www.transparencymarketresearch.com/testosterone-replacement-therapy.html

However, the market is currently at a crucial juncture with top performing products losing their patents in the next few years. This will no doubt cause a major dent in revenues of key market players. However, some of this impact could be reduced by the heightened demand for and awareness levels about the benefits of advanced TRT products. Many of these products are now being utilized in testosterone deficiency treatment are likely to support market growth during the forecast period.

TRT Creams and Gels Continue to See Strong Sales Worldwide but Injections Racing Ahead

For the purpose of this study, the global testosterone replacement therapy market has been segmented on the basis of product type into creams/gels, patches, injections, gums/buccal adhesives, implants and oral drug forms. Of these, the creams/gels segment led the global market, as overall sales were mainly impelled by key branded formulations such as AndroGel from AbbVie, Inc. Axiron from Eli Lilly and Company, and Fortesta, Testim, and Natesto from Endo Pharmaceuticals Inc.

Get Sample with Latest Research @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1097

Ease of use and comparatively less side effects have been the winning characteristics of gels/cream TRT products. However, this segment is expected to lose its current hold on the market owing to patent expirations of branded formulations.

TMR expects the injections product segment to witness the fastest CAGR from 2016 to 2024. This will be possible mainly because consumers are now more open to using these low priced products a factor aided by the increasing availability of self-administered forms of these products globally.

On the basis of active ingredients, the TRT market is segmented into testosterone, methyl testosterone, testosterone undecanoate, and testosterone enanthate and testosterone cypionate. Of these, testosterone as an active ingredient dominated the global TRT market in 2015. However, other active ingredients are expected to cover much ground through the forecast period. The demand for ester forms of testosterone such as testosterone cypionate and testosterone undecanoate is projected to show a healthy rise. Testosterone undecanoate is expected to witness the fastest growth through the reports forecasting horizon from 2016 to 2024.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1097

North America Leads TRT Market but Scales Tipping in Favor of Asia Pacific

Of the five broad geographical segments of the global testosterone replacement therapy market, North America accounted for the largest share (84.7%) of the market and was followed by Europe In 2015. The other key segments are Europe, Asia Pacific, Middle East and Africa (MEA), and Latin America.

The demand for advanced TRT products was especially strong in the U.S. in 2015 as the country accounted for 95% of the North America TRT market in that year, TMR has observed. Asia Pacific will greatly benefit from higher healthcare investments being channeled into the region and is expected to witness the fastest CAGR in the TRT market during the forecast period. China and India are markets that companies in the TRT market cannot ignore. In South Korea and Japan, on the other hand, the sizeable geriatric population and strong positive sentiments will aid the consumption of TRT products. Brazil is the key TRT market in Latin America with the single largest share 2015.

The key players operating in the global testosterone replacement therapy market are AbbVie, Inc., Allergan plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Mylan N.V., Novartis AG, and Pfizer, Inc. The testosterone replacement therapy market is somewhat consolidated with presence of a few large global players and some local vendors that are operating in the international market.

View original post here:
Testosterone Replacement Therapy Market: Increase in Incidence of Testosterone Deficiency to Drive the Global Market - Online News Guru

A new study published at the Journal of Urology shows a significant improvement in sexual and urinary functions and in the quality of life of men with hypogonadism who undergo long-term testosterone replacement therapy.

Urinary Health

Testosterone is a steroid hormone involved in the regulation of sexual function, urinary tract health and metabolism, as well as other important functions. In most men, testosterone levels decrease slowly with age and cannot cause immediate serious symptoms. However, some people may experience many signs and symptoms, such as a clinical condition called testosterone deficiency (TD) or male hypogonadism, which is attributed to inadequate testosterone levels. As a result, they experience symptoms ranging from fatigue, erectile dysfunction, low energy, decreased mood, and increased risk of diabetes.

Scientists from the Boston University School of Medicine have worked with a group of urologists in Germany to investigate the effects of prolonged testosterone replacement therapy on urinary tract health, sexual function, and quality of life of men with diagnosed symptomatic testosterone deficits. The study included more than 650 men aged between 50 and 60, some with an unexplained testosterone deficiency and others with known genetic and autoimmune causes of hypogonadism.

Testosterone treatment in men would enlarge the prostate and aggravate symptoms of the lower urinary tract according to Dr. Abdulmaged Traish a professor of urology at BUSM.

However, he and Dr. Gheorghe Doros, professor of biostatistics at BUSPH, discovered that despite the increased size of the prostate in the testosterone therapy group, there were fewer urinary symptoms such as frequent urination, incomplete emptying of the bladder, weak urine flow and waking up at night.

In addition to these subjective improvements, scientists conducted objective tests that showed that men who were treated with testosterone emptied their bladders more completely. Finally, testosterone treatment also increased patient outcomes based on the evaluation of their sexual erection health and overall quality of life.

The results of this study are of great importance for men with symptomatic testosterone deficits. Traish emphasized the value of this treatment option and stated that testosterone therapy is well tolerated with progressive and continuous improvement of urinary and sexual function and overall quality of life.

Read this article:
Testosterone Therapy Can Improve Urinary and Sexual Function in Men with Low T - Gilmore Health News

Hate group leaderMichelle Cretella of American College of Pediatricians dispenses medical advice based on Church dogma, not medical science.

via YouTube

The problem is: the thousands of people who die while taking these drugs are likely the terminally ill cancer patients who receive hormone blockers to fight hormone-sensitive cancers, like prostate cancer, according to experts.

Enter hate group leader Michelle Cretella (American College of Pediatricians)

She also pointed out that the FDA report shows that there were 11 deaths of children linked to this drug, none of whom were being treated for prostate cancer.

Without her knowledge, someone injected this crank with some sodium pentothol:

The use of Lupron to block puberty in children with gender dysphoria is not FDA approved in short because puberty is not a disease, she said.

In fact, giving puberty blockers to physically healthy children induces the disease known as hypogonadotrophic hypogonadism.

None of this blather has anything whatsoever to do with the wellbeing of children. The intent is to defend the teachings of the Catholic Church. At the risk of being repetitive, belief systems are based on faith. Medical science is based on evidence. The Church is out of bounds for attempting to conform the science to religious dogma.

Not treating pediatric gender dysphoria poses a significant risk of self-harm. Not treating pediatric gender dysphoria because of Catholic dogma is irresponsible and stunningly stupid. Any parent who follows Cretella's advice or the ramblings of LifeSiteNews is guilty of child abuse. Cretella's former professional society, the American Academy of Pediatrics, recommends gender-affirming care. That is based on exhaustive study.

Who are you going to listen to? A religious crank who has not practiced medicine in years (presumably to avoid continuing education obligations) or the professional associations whose only concern is the wellbeing of children?

Related content:

Read the original here:
Michelle Cretella whittles down "thousands of deaths" to 11 - The Slowly Boiled Frog

Anabolic steroids additionally called androgenic steroids are derivatives of testosterone, significant for advancing and keeping up muscle development and creating auxiliary male sex qualities, for example, an extending voice and facial hair. They are anabolic and increment protein inside cells, particularly in skeletal muscles, Anabolic steroids utilized restoratively in ailments to animate muscle increment, set off male adolescence and treat constant squandering conditions, comprising of malignancy and AIDS.

Increment in geriatric populace drives the androgens and anabolic steroids commercial center, as more men are susceptible to hypogonadism. Also, ascend in weight issues in men propels the overall androgens and anabolic steroids market. The growing negative health status specifically within the developing countries is projected to fuel the growth of the marketplace during the forecast period. Besides, rise in government ventures for higher human services is attributed to the growth of the overall androgens and anabolic steroids market. Increment in occurrence of hypogonadism among men is anticipated to enlarge the worldwide androgens and anabolic steroids market all through the forecast span. Rise in impotence among men due to weight problems and tiredness is expected to enhance demand for androgens and anabolic steroids during forecast duration.

Request for Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/29509

Anabolic Steroids Market can be segmented on basis of compound derivatives, mode of administration, applications, Distribution channels and geography.

On basis of synthetic derivatives, Anabolic steroids market is segmented as:

On basis of Modes of administration, Anabolic steroids is segmented as:

On basis of Applications, anabolic steroids is segmented as:

On basis of Distribution channels, anabolic steroids market is segmented as:

Anabolic steroids include di-hydro-testosterone, testosterone, and other marketers. Anabolic steroids stimulate the improvement of male sex organs and male sexual characters including growth of beard and deepening of voice. Various varieties of tissues grow due to stimulation of anabolic steroids, specifically muscle and bone. Rise in red blood cells production is due to anabolic results. Androgens and anabolic steroids are used for the remedy of breast cancer in ladies, impotence, hypogonadism in men, and alternative therapy delayed puberty in adolescent boys. Anabolic steroids are also used for the treatment of numerous conditions with hormonal imbalance, weight loss, osteoporosis, and anemia. Anabolic steroids market can be segmented based on synthetic derivatives, mode of administration, application, end-user, and region. In terms of mode of administration, the market can be categorized into oral, injection, topical, skin patches and inhaler. Based on application type, anabolic steroids market can be divided into Anabolic, Androgenic and others. Based on distribution channels anabolic steroids market can be classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market owing to elevated availability of medications and hospitals being the first point of contact for treatment.

If you have any query, ask the analyst @ https://www.persistencemarketresearch.com/ask-an-expert/29509

Anabolic steroids market in North America held the biggest marketplace share due to expanded prevalence of breast cancer in women. According to many researches, breast cancers is one of the main cause of death in U.S. Europe held the second largest share in anabolic steroids market because of accelerated occurrence of hypogonadism in men and delayed puberty in adolescent boys. The Anabolic steroids market in Asia Pacific is expected to grow at a fast pace during the forecast period attributable to multiplied government initiatives to get rid of breast cancer. Anabolic steroids market in Middle East & Africa is predicted to be driven via improved occurrence of impotence, hypogonadism in men, and behind schedule puberty in adolescent boys. The market in Latin America is projected to witness robust increase at some point of the forecast length due to accelerated government tasks within the fitness care sector.

Valeant, Endo Pharmaceuticals Solutions Inc., Germiphene Corporation, Taro Pharmaceuticals, Inc., Antares Pharma, Inc, Actavis Pharma, Inc, Sandoz, Pfizer, Unimed Pharmaceuticals, Upsher-Smith and others

See original here:
Rapid Advancements in Anabolic Steroids Market to Fuel Revenues Through 2029 - Space Market Research

A newly designed viral vector the vehicle that delivers a gene therapyto a patients cells for use insickle cell anemia is more efficient than earlier vectors at introducing healthy copies of genes into stem cells and can be produced in greater amounts, studies in animal models show.

The study Development of a forward-orientated therapeutic lentiviral vector for hemoglobin disorders was published in the journal Nature Communications.

Hemoglobin is the protein in red blood cells that binds oxygen, allowing oxygen to be transported around the body. Mutations in the HBBgene, which encodes a component of hemoglobin, causessickle cell.

Gene therapies involve either altering the mutated gene or introducing a healthy version of that gene to the body. Still under development for sickle cell, an estimated 27 patients have undergone experimental gene therapy. One strategy involves removing hematopoietic stem cells (which function to produce blood cells) from a patients bone marrow. A healthy copy of the HBB gene is then introduced into the cells using a modified, harmless virus known as a viral vector. The cells are then transplanted back into the patient where they will produce healthy red blood cells.

Traditionally, viral vectors for sickle cell have been designed in a way known as reverse structural orientation. This means that the HBB gene is translated or read from right to left, like reading an English sentence backwards. The reverse structural orientation design ensures that a key section of the gene (known as intron 2), which is necessary for the production of high levels of the HBB gene, is retained during viral vector preparation.

However, this design makes preparing the viral vectors more difficult, and decreases the efficiency of introducing the gene into the stem cells.

Researchersat the National Institutes of Healthdesigned a new viral vector, one in which the HBB gene is forward orientated and read from left to right. Genes essential for the virus were inserted into intron 2, meaning that only vectors that retained intron 2 would be produced (a type of positive selection).

Our new vector is an important breakthrough in the field of gene therapy for sickle cell disease, John Tisdale, MD, chief of the Cellular and Molecular Therapeutic Branch at the National Heart, Lung, and Blood Institute (NHLBI) and the studys senior author, said in a press release.

Its the new kid on the block and represents a substantial improvement in our ability to produce high capacity, high efficiency vectors for treating this devastating disorder, he added.

The researchers compared the new vectors to traditional reverse-orientated vectors in mouse and monkey models. The new vectors were four to 10 times more efficient at introducing the healthy HBBgene into the stem cells, and could carry up to six times more HBB genes compared to the conventional vectors.

Furthermore, the new vectors remained incorporated into the cells of monkeys up to four years after a transplant. These vectors could also be produced in greater amounts, which may lessen the time and costs required for large-scale vector production.

The researchers hope that these characteristics will make gene therapy for sickle cell disease more effective and increase its use. The new vector design still needs to be tested in clinical trials in patients.

Our lab has been working on improving beta-globin vectors for almost a decade and finally decided to try something radically different and it worked, Tisdale said.

These findings bring us closer to a curative gene therapy approach for hemoglobin disorders, he added.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Total Posts: 94

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Read the original here:
New Viral Vector for Sickle Cell Gene Therapy Likely to Be More Effective, NIH Study Says - Sickle Cell Anemia News

PENNY Lancaster was reduced to tears as she handed five-year-old Ronnie Musselwhite the Young Hero gong at The Suns Who Cares Wins health awards last night.

Spurs fan Ronnie bravely offered to give his older sister Ebonie a bone marrow transplant last year.

Eight-year-old Ebonie had leukaemia and it was her only hope.

Mum Christine Jenkins, 40, said: Ronnies stem cells worked perfectly. They did what they were supposed to do but the leukaemia came back somewhere new.

Ebonie, of Crawley, West Sussex, nominated her younger brother before her death in June.

Rod Stewarts partner Penny chatted with Ronnie about his love of football and Spurs.

She said: To say I am humbled to be here is an understatement. Sometimes you think life has turned a corner on you, but then someone else turns up to give you some inspiration.

"The courage this little man has shown is absolutely incredible. Hes only five years old, hes lost a sister.

"He was incredibly shy to stand up in front of everyone to collect his award, but he again was so brave.

Christine said: We want Ronnie to know that what he did still worked, was still brave, even though he lost his sister.

PM Boris Johnson was also at the awards held at The Suns London HQ near The Shard and paid tribute to our NHS heroes.

He presented an award to a pair of quick-thinking hospital porters who saved the life of a seven-week-old baby boy.

Nick Evans, 48, and Ruth Lowe, 47, sprang into action after Logan Clifford stopped breathing.

His parents, Sarah and Mike were visiting a relative at the Princess Royal Hospital in Telford, Shrops, when they noticed Logans lips had turned blue.

Sarahs screams alerted Ruth, who shouted for Nick. He grabbed Logan and performed CPR as he ran half a mile down the corridor to A&E.

Nick continued CPR until the resuscitation team took over and the porters stayed by Logans parents side until they knew he was going to be OK. Sarah, 30, has called the two porters my heroes.

As he handed the pair the Ultimate Lifesaver trophy, the PM said: The NHS is revered around the world, and in no small part due to the heroes working in it every day.

He added: My experience of the NHS is like everybody else in the NHS - one of admiration and love.

"It is the most extraordinary institution in the world. If our country was an omelette then the NHS is the egg white that holds the great British cake together.

Virgin Radio DJ Chris Evans presented the Best Nurse gong to Liz Monaghan, 53. She set up the widely praised Purple Rose initiative, which aims to improve the care for patients and their loved ones in the last days of their life.

Liz, who works at the Florence Nightingale Hospice, based at the Stoke Mandeville Hospital in Aylesbury, Bucks, said: Im a little embarrassed to have won. Im a small part of a big team.

DJ Chris said: Youve got to prepare yourself for nights like this because otherwise they hit you like an express train.

Who Cares Wins Awards: The winners

BEST HEALTH CHARITY

Winner: Matt Hampson Foundation

Former English rugby union player Matt Hampson set up a charity to help others after being left paralysed in a scrum in 2005.

Other nominees: Superhero Foundation and Team Domenica

BEST NEONATAL SPECIALIST

Winner: Professor Kypros Nicolaides

Professor Nicolaides performed pioneering keyhole surgeon on Sherrie Sharps unborn son Jaxon. By extraordinary coincidence, as a young surgeon, he also operated on Sherries mother when she was in the womb.

Other nominees: Dr Vesna Pavasovic and Professor Massimo Caputo

UNSUNG HERO

Winner: Therapeutic Care Volunteers at South Tees NHS Foundation Trust

30 therapeutic care volunteers, who all have a learning or physical disability, give up their time to support patients with spinal injuries at The James Cook University Hospital in Middlesbrough. They include Ify Nwokoro.

Other nominees: Ben Slack and Rob Allen

GROUNDBREAKING PIONEER

Winner: Guys and St Thomas London Auditory Brainstem Implant (ABI) Service

Leia Armitage, eight, was born with a rare form of deafness and was never expected to speak. But she now can thanks to pioneering brain surgery and speech therapy carried out by Guys and St Thomas London Auditory Brainstem Implant (ABI) Service.

Other nominees: Dr Helen Spencer and Girish Vajramani

BEST DOCTOR

Winner: Dr Matthew Boulter

Dr Boulter served in Afghanistan, teaches wild trauma to army medics and his surgery became the first in Cornwall to be given veteran friendly accreditation.

Other nominees: Margaret France and Dr Bijay Sinha

BEST MIDWIFE

Winner: Jane Parke

Jane helped deliver the youngest surviving twin boys in Britain when they were born at 22 weeks last year. She flew 190 miles with their mum Jennie Powell to a specialist neonatal unit.

Other nominees: Charlotte Day and Nagmeh Teymourian

ULTIMATE LIFESAVER

Winner: Ruth Lowe and Nick Evans

Porters Ruth and Nick saved the life of Sarah and Mike Cliffords seven-week-old baby Logan. He stopped breathing as they walked through the main entrance of The Princess Royal Hospital in Telford to visit a sick relative.

Other nominees: Dr Mark Forrest and Mike Merrett

BEST NURSE

Winner: Liz Monaghan

Liz is the Matron of the Florence Nightingale Hospice in Aylesbury, Bucks, and came up with the idea for the widely praised Purple Rose initiative to improve the care for patients in the last days of their lives.

Other nominees: Margaret Ballard and Carlton DeCosta

MENTAL HEALTH HERO

Winner: Ben West

Ben lost his brother Sam, 15, to suicide last year and since his death, has campaigned tirelessly to raise awareness for mental health.

Other nominees: Beth Gregan and Catherine Benfield

YOUNG HERO

Winner: Ronnie Musselwhite

Ronnie offered to help his sister Ebonie by giving her a bone marrow transplant when she was diagnosed with a rare form of leukaemia. Ebonie nominated her brother for his bravery before she died in June.

Other nominees: Bella Field and Kaitlyn Wright

I only walked ten metres into the room tonight and I already nearly burst into tears three times.

TV star Christine Lampard gave the Best Neonatal Specialist award to Prof Kypros Nicolaides, 66.

He was nominated by Sherrie Sharp, 29, of Horsham, West Sussex, for saving the life of her unborn baby son and her own.

After scans revealed Jaxson had spina bifida, Sherrie was offered a termination. But she contacted Prof Nicolaides, a surgeon at Kings College Hospital, London.

He had saved her life 30 years earlier when she developed a rare blood disorder in her mums womb.

He agreed to perform ground-breaking surgery on Jaxson while he was in Sherries womb.

Prof Nicolaides said: I was delighted to be able to help. Sherrie said: He has saved so many generations of my family. Hes our guardian angel.

The Who Cares Wins Awards were set up in 2017 by The Sun to honour the nations heroic doctors, nurses, midwives, other NHS staff and volunteers.

The Duchess of York presented an award to the parents of Natasha Ednan-Laperouse, 15, who died of an allergic reaction to a sandwich from Pret.

The duchess said: Can I just say to The Sun, I think youre incredible. Every minute Im sitting there and thinking Im so lucky. The NHS, The Sun and all of you, this is what makes Britain so great.

Lorraine Kelly, who presented the awards, said: Earlier on this year my dad was very sick and we honestly thought we were going to lose him.

"It was really difficult and it was only because of the efforts of the NHS hes still here. Its fantastic.

Who Cares Wins Awards: The winners

BEST HEALTH CHARITY

Nominees: Superhero Foundation

Team Domenica

Winner: Matt Hampson Foundation

Former English rugby union player Matt Hampson set up a charity to help others after being left paralysed in a scrum in 2005.

BEST NEONATAL SPECIALIST

Nominees: Dr Vesna Pavasovic

Professor Massimo Caputo

Winner: Professor Kypros Nicolaides

Professor Nicolaides performed pioneering keyhole surgeon on Sherrie Sharps unborn son Jaxon. By extraordinary coincidence, as a young surgeon, he also operated on Sherries mother when she was in the womb.

UNSUNG HERO

Nominees: Ben Slack

Rob Allen

Winner: Therapeutic Care Volunteers at South Tees NHS Foundation Trust

30 therapeutic care volunteers, who all have a learning or physical disability, give up their time to support patients with spinal injuries at The James Cook University Hospital in Middlesbrough. They include Ify Nwokoro.

GROUNDBREAKING PIONEER

Nominees: Dr Helen Spencer

Girish Vajramani

Winner: Guys and St Thomas London Auditory Brainstem Implant (ABI) Service

Leia Armitage, eight, was born with a rare form of deafness and was never expected to speak. But she now can thanks to pioneering brain surgery and speech therapy carried out by Guys and St Thomas London Auditory Brainstem Implant (ABI) Service.

BEST DOCTOR

Nominees: Margaret France

Dr Bijay Sinha

Winner: Dr Matthew Boulter

Visit link:
Penny Lancaster is reduced to tears as she gives bone marrow donor Ronnie Musselwhite, 5, The Suns Young H - The Sun

Global Cell Therapy Technologies Market was valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/#requestforsample

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

Do Inquiry Before Purchasing Report Here: https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/#inquiry

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at: https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Follow this link:
Global Cell Therapy Technologies Market Industry Analysis and Forecast (2018-2026) - Weekly Spy

Mathew Knowles, father to Beyonc and Solange, revealed on "Good Morning America" that he's been battling breast cancer. USA TODAY

As Breast Cancer Awareness Month begins, few people think about the men affected.

Beyoncs father, Mathew Knowles, revealed on "Good Morning America"Wednesday that he is battling breast cancer and urged other men to get tested for the disease.

The American Cancer Society estimates about 2,670 new cases of invasive male breast cancer will be diagnosed in the USAin 2019, and about 500 men will die from the disease.

Mary Smania, assistant professor at Michigan State University's College of Nursing, said breast cancer in men is extremely rare less than 1% butcarries dangerous consequences.

Should you get a 3D mammogram?: What you should know about how the screening detects breast cancer

The American Cancer Society lists signs and symptoms of male breast cancer:

Sometimes breast cancer can spread and cause swellingunder the arm or around the collar bone, even before the original tumor in the breast isn't big enough to be felt, according to the organization.

"It's a little bit easier to detect," Smania said. "Typically because they don't have the amount of breast tissue that women have."

Routine breast screenings don't exist for men likethey do for women, Smania said, so it's important to see a health care professional with any concerns.

Lyndsay Rhodes, associate professor of biological sciences at Florida Gulf Coast University, said knowing the symptoms is a great first step to early detection.

"Being aware of symptoms can save lives," Rhodes said. "Early detection is key."

Battling cancer for the 3rd time: Olivia Newton-John 'had to learn to walk again' amid stage 4 breast cancer battle

The ACS noted that cells in nearly any part of the body can be susceptible to cancer and can spread to other areas of the body.

The organization's website says cancer can start at different parts of the breast, such in the ducts that carry milkto the nipple or the glands that make breastmilk. Although men's breasts don't produce milk like women's, their bodies havethese ducts and glands.

Smania said the most common form of breast cancer in men is the invasive ductal carcinoma, which the ACS said starts in the milk duct, breaks through the wall of the duct,then grows into the fatty tissue of the breast where it has the potential to spread.

An athlete's battle: Syracuse basketball star perseveres in breast cancer fight

When a man is diagnosed with breast cancer, Smania said, doctors usually do genetic testing as well to determine if he carries BRCA1 or BRCA2 mutations, also known by the National Breast Cancer Foundation as the "Breast Cancer Gene."

These mutations are genetic and can be passed down to children, which would significantly increase the chances of a daughter having breast cancer, Smania said.

The National Breast Cancer Foundation said 55%-65% of women with the BRCA1 mutation and about 45%with the BRCA2 mutation will develop breast cancer by the age of 70.

"Education in this matter is critical," Rhodes said."Men are statistically less likely to have a primary care physician, go to yearly examsor conduct self breast exams."

'Im lucky to be alive': '90210' star Shannen Doherty gets candid on breast cancer battle

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/news/health/2019/10/02/beyonces-dad-has-male-breast-cancer-what-symptoms/3839922002/

Continue reading here:
Male breast cancer awareness: Why Beyonce's father, Mathew Knowles, urges men to get tested - USA TODAY